Substitute f	form 1449A/PTO			Со	mplete if Known
				Application Number	10/562,478
INFORMATION DISCLOSURE				Filing Date	11-15-2006
STATE	STATEMENT BY APPLICANT			First Named Inventor	Gordana Kosutic
				Group Art Unit	1656
(use as many sheets as necessary)		Examiner Name	Liu, Samuel		
Sheet	1			Attorney Docket Number	014811-487.114

Examiner	Cite	U.S. Patent D	ocument	Name of Patentee or	Date of Publication of Cited Document
Initials*	No.	Number	Kind Code (if known)	Applicant of Cited Document	MM-DD-YYYY
***************************************		3,256,153		Heimlech	6-14-1966
		3,868,356		Smyth	2-25-1975
***************************************		3,919,411		Glass et al.	11-11-1975
		3,950,517		Lindsay et al.	4-13-1976
		4,003,792		Mill et al	1-18-1977
		4,044,196		Huper et al	8-23-1977
•		4,087,390		Shields	5-2-1978
		4,093,574		Shields	6-6-1978
		4,100,117		Shields	7-11-1978
		4,179,337		Davis et al	12-18-1979
***************************************		4,223,163		Guilloty	9-16-1980
		4,229,438		Fujino et al	10-21-1980
***************************************		4,253,998		Sarantakis	3-3-1981
		4,277,394		Fujino et al	7-7-1981
		4,338,306		Kitao et al	7-6-1982
		4,348,387		Brownlee et al	9-7-1982
•••••		4,410,547		Ueno et al	10-18-1983
		4,469,681		Brownlee et al	9-4-1984
		4,472,382		Labrie et al	9-18-1984
***************************************		4,526,938		Churchill et al	7-2-1985
***************************************		4,544,101		Норр	11-19-1985
		4,579,730		Kidron et al	4-1-1986
•••••	1	4,585,754		Meisner et al	4-29-1986
************		4,662,392		Vadasz	5-5-1987
		4,684,524		Eckenhoff et al	8-4-1987
		4,698,264		Steinke	10-6-1987
***************************************		4,717,566		Eckenhoff et al	1-5-1988
•••••		4,772,471		Vanlerberghe et al	9-20-1988
		4,774,976		Vanlerberghe et al	10-4-1988
	1	4,797,288		Sharma et al	1-10-1989
		4,801,575		Pardridge	1-31-1989
	<u> </u>	4,839,341		Massey et al	6-13-1989
	1	4,840,799		Applegren et al	6-20-1989
***************************************		4,849,405		Ecanow	7-18-1989
		4,917,888		Katre et al	4-17-1990
		4,935,246		Ahrens	6-19-1990
***************************************		4,946,828		Markussen	8-7-1990
		4,957,910		Sutton et al	9-18-1990
		4,963,367		Ecanow	10-16-1990
	1	4,963,526		Ecanow	10-16-1990
•••••	1	4,994,439	***************************************	Longenecker et al	2-19-1991
		5,013,556		Woodle et al	5-7-1991
***************************************	1	5,055,300		Gupta	10-8-1991
***************************************	†	5.055,304		Makino et al	10-8-1991
	1	5,089,261		Nitecki et al	2-18-1992
·····	1	5,093,198		Speaker et al	3-3-1992
	1	5,099,074		Mueller et al	3-24-1992
	1	5,108,568		Van Alstine	4-28-1992

| 10/25/2010 | TRIT-676091v1 | An Alstine | 4-28-1992 | TRIT-676091v1 | Date Considered | 10/25/2010 | TRIT-676091v1 | TRIT-676091v1 | Date Considered | 10/25/2010 | TRIT-676091v1 | TRIT-676

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute 1	form 1449A/PTO			Con	mplete if Known
		A 21188		Application Number	10/562,478
INFORM	ATION DISCL	OSURE		Filing Date	11-15-2006
STATE	STATEMENT BY APPLICANT			First Named Inventor	Gordana Kosutic
			Group Art Unit	1656	
(use as ma	(use as many sheets as necessary)		Examiner Name	Liu, Samuel	
Sheet	2			Attorney Docket Number	014811-487.114

5,122,614	Zalipsky	6-16-1992
5,157,021	Balshmidt et al	10-20-1992
5,162,430	Rhee et al	11-10-1992
5,164,366	Balschmidt et al	11-17-1992
5,202,415	Jonassen et al	4-13-1993
5,206,219	Desai	4-27-1993
5,283,236	Chiou	2-1-1994
5,286,637	Veronese et al	2-15-1994
5,292,802	Rhee et al	3-8-1994
5,298,410	Phillips et al	3-29-1994
5,304,473	Belagaje et al	4-19-1994
5,308,889	Rhee et al	5-3-1994
5,312,808	Shorr et al	5-17-1994
5,320,840	Camble et al	6-14-1994
5,324,775	Rhee et al	6-28-1994
5,328,955	Rhee et al	7-12-1994
5,349,052	Delgado et al	9-20-1994
5,359,030	Ekwuribe	10-25-1994
5,405,621	Sipos	4-11-1995
5,405,877	Greenwald et al	4-11-1995
5,413,791	Rhee et al	5-9-1995
5,415,872	Sipos	5-16-1995
5,428,128	Mensi-Fattohi et al	6-27-1995
5,438,040	Ekwuribe	8-1-1995
5,444,041	Owen et al	8-22-1995
5,446,091	Rhee et al	8-29-1995
5,457,066	Frank et al	10-10-1995
5,461,031	De Felippis	10-24-1995
5,468,478	Saifer et al	11-21-1995
5,504,188	Baker et al	4-2-1996
5,506,203	Backstrom et al	4-9-1996
5,518,998	Backstrom et al	5-21-1996
5,523,348	Rhee et al	6-4-1996
5,529,915	Phillips et al	6-25-1996
5,545,618	Buckley et al	8-13-1996
5,550,188	Rhee et al	8-27-1996
5,567,422	Greenwald	10-22-1996
5,597,797	Clark	1-28-1997
5,606,038	Regen	2-25-1997
5,612,460	Zalipsky	3-18-1997
5,631,347	Baker et al	5-20-1997
5,637,749	Greenwald	6-10-1997
5,643,575	Martinez et al	7-1-1997
5,646,242	Baker et al	7-8-1997
5,650,388	Shorr et al	7-22-1997
5,658,878	Backstrom et al	8-19-1997
5,681,567	Martinez et al	10-28-1997
5,681,811	Ekwuribe	10-28-1997
5,693,609	Baker et al	12-2-1997
5,693,769	Kahne et al	12-2-1997
5,700,904	Baker et al	12-23-1997

7881-676091v3 /Samuel Liu/ Date Considered 10/25/2010

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute 1	form 1449A/PTO			Co	mplete if Known
				Application Number	10/562,478
INFORM	ATION DISCL	OSURE		Filing Date	11-15-2006
STATE	STATEMENT BY APPLICANT			First Named Inventor	Gordana Kosutic
			Group Art Unit	1656	
(use as ma	(use as many sheets as necessary)		Examiner Name	Liu, Samuel	
Sheet	3			Attorney Docket Number	014811-487.114

5,707,648	Yiv	1-13-1998
5,714,639	Bowman et al	2-3-1998
5,738,846	Greenwald et al	4-14-1998
5,747,445	Backstrom et al	5-5-1998
5,747,642	De Felippis	5-5-1998
5,750,497	Havelund et al	5-12-1998
5,763,396	Weiner et al	6-9-1998
5,766,620	Heiber et al	6-16-1998
5.773,581	Camble et al	6-30-1998
5,824,638	Burnside et al	10-20-1998
5,830,853	Backstrom et al	11-3-1998
5,830,918	Sportsman et al	11-3-1998
5,843,866	Parker et al	12-1-1998
5,849,860	Hakimi et al	12-15-1998
5,853,748	New	12-29-1998
5,854,208	Jones et al	12-29-1998
5,856,451	Olsen et al	1-5-1999
5,866,538	Norup et al	2-2-1999
5,866,584	Cincotta et al	2-2-1999
5,874,111	Maitra et al	2-23-1999
5,898,028	Jensen et al	4-27-1999
5,902,588	Greenwald et al	5-11-1999
5.905,140	Hansen	5-18-1999
5,907,030	Shen et al	5-25-1999
5,922,675	Baker et al	7-13-1999
5,932,462	Harris et al	8-3-1999
5,942,248	Barnwell	8-24-1999
5,948,751	Kimer et al	9-7-1999
5,952,008	Backstrom et al	9-14-1999
5,952,297	De Felippis et al	9-14-1999
5,962,267	Shin et al	10-5-1999
5,968,549	New et al	10-19-1999
5,969,040	Hallahan et al	10-19-1999
5,981,709	Greenwald et al	11-9-1999
5,985,283	Lee et al	11-16-1999
6,004,574	Backstrom et al	12-21-1999
6,011,008	Domb et al	1-4-2000
6,025,325	Campfield et al	2-15-2000
6,034,054	De Felippis et al	3-7-2000
6,042,822	Gilbert et al	3-28-2000
6,043,214	Jensen et al	3-28-2000
6,051,551	Hughes et al	4-18-2000
6,057,292	Cunningham et al	5-2-2000
6,063,761	Jones et al	5-16-2000
6,093,391	Kabanov et al	7-25-2000
6,113,906	Greenwald et al	9-5-2000
6,165,976	Backstrom et al	12-26-2000
6,177,087	Grenwald et al	1-23-2001
6,191,105	Ekwuribe et al	2-20-2001
6,200,602	Watts et al	3-13-2001
6,211,144	Havelund	4-3-2001

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute	form 14	49A/PTO			•••••	Con	plete if K	nown
				 	Application N		10/562,47	
NFORM	MOITA	V DISCL	LOSURE		Filing Date		11-15-200	***************************************
STATE	MENT	BY AI	PPLICANT		First Named	Inventor	Gordana I	
					Group Art Un		1656	
use as m	any shee	ets as nec	essary)		Examiner Na	me	Liu, Samu	iel .
Sheet	6,248,363 6,251,856 6,258,377 6,268,335 6,306,440 6,309,633 6,310,038 6,323,311 6,335,316 6,342,225 6,352,974 6,506,730 6,713,452 7,030,082 6,858,580 6,191,105 6,828,297				Attorney Doc	kat Number	014811-4	Q7 41A
Ji ree c	14		.1		Audities Doc	NOT (ACUITO)	0140174	
******************************		6,248,3	363		Patel et	al	6-19-200)1
		6,251,8	156		Markuss	en et al	6-26-200)1
					New et a		7-10-200	
					Brader		7-31-200	
					Backstro		10-23-20	
					Ekwuribe	***************************************	10-30-20	
*************	 				Havelun	3	10-30-20	
					Liu et al	nk al	11-27-20	
***************************************					Hughes d		1-29-200	
***************************************					Ghirri et		3-5-2002	
	+	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~			Lee et al		1-14-200	
***************************************	†				Ekwuribe		3-30-200	
					Soltero e		4-18-200	
		6,858,5	i80		Ekwuribe	et al	2-22-200	
		6,191,1	05		Ekwuribe	et al	2-20-200)1
		6,828,2	297		Ekwuribe	et al	2-22-200)5
				US Pu	blished Applica	tions		
Examiner nitials*)			Date				
		2002/0160938		10-31-	2002	Brandenbu	irg et al.	
		2003/	0004304	1-2-20	03	Ekwuribe	et al	
	-	-4		2-6-20		Ekwuribe		
······	 		·····	2-6-20	~~~~~	Ekwuribe		
	ļ		······		~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~		~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	
		4		3-13-2	•••••••	Ekwuribe		
		2003/	0060606	3-27-2	:003	Ekwuribe	et al	
		2003/	0069170	4-10-2	003	Soltero et a	al	
***************************************	-	2003/	0083232	5-1-20	n) i	Soltero et	a1	
	†			5-8-20		Soltero et		
		-4						
				7-31-2		Ekwuribe	et al	
		2003/	0153488	8-14-2	:003	May et al		
		2004/	0017387	1-29-2	:004	Soltero et a	al	
		2004/	0038867	2-24-2	004	Still et al.		
		·•···		.			D 41	
	ļ	·		12-11-	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	Krishnan,	~~~~~~~~~	
***************************************	ļ		~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	2-26-2		Soltero et	·····	
		2003/	0229009	12-11-	2003	Soltero et a	<u>al</u>	
		2004/	0091452	5-13-2	004	Ekwuribe	et al	
xaminer		-	Foreign Patent Docur	nent		f Patentee or	Date of	Publication of Cited Document
nitials*	No.	Office	Number	Kind Code (if known)	- Applicant of	Cited Document		MM-DD-YYYY
		· 	ED 0004503	101064131	Masahiko,	Called	7-8-1981	
		3	EP 0031567	•	i wasaniko.	runno	(LOUISD)	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute form 1449A/PTO	Con	iplete if Known
INFORMATION PIONE POLITICAL	Application Number	10/562,478
INFORMATION DISCLOSURE	Filing Date	11-15-2006
STATEMENT BY APPLICANT	First Named Inventor	Gordana Kosutic
	Group Art Unit	1656
(use as many sheets as necessary)	Examiner Name	Liu, Samuel
Sheet 5	Attorney Docket Number	014811-487.114

EP 0092918	A2	Churchill, Jeffrey	11-2-1983
EP 0354855	A2	Yoshida, Hiroshi	2-14-1990
EP 0381070	A1	Butelman, Edoardo	8-8-1990
EP 0483465	B1	Salama et al	8-2-1992
EP 0511903	A2	Wantier, Henry	11-4-1992
EP 0483465		Salama et al	8-6-1995
EP 0597007		Constantinides, Panayiotis	10-16-1996
EP 0621777		Wunderlich et al	11-2-1996
EP 0797615	81	Coombs et al	1-13-1997
EP 0822218	A2	Miller et al	2-4-1998
GB 1492997		Smyth, Derek G.	11-23-1977
JP 01207320		Motoyuki, Ishikura	8-21-1989
JP 1254699		Muranishi, Shozo	10-11-1989
WO 93/01802		Heimgartner, Frederic	2-4-1993
WO 94/23740		Bentz, Johanna	10-27-1994
WO 95/09831		Del Soldato, Piero	4-13-1995
WO 95/30641		Del Soldato, Piero	11-16-1995
WO 97/14740		Morgan, A.	4-24-1997
WO 98/07745		Fraser, Janet	2-26-1998
WO 99/32134		Lee, Seoju	7-1-1999
WO 99/65941		Jones, Richard	12-23-1999
WO 00/43034		Kingman, NG	7-27-2000
WO 00/78302	A1	Ekwuribe, W.	12-28-2000
WO 01/12230		Park, Myung-ok	2-22-2001
WO 02/09766	A1	Park, Myung-ok	2-22-2001
WO 02/098232	A1	Ekwuribe, W.	12-12-2002
WO 02/098446	A1	Ekwuribe, W	12-12-2002
WO 03/022208	A2	Soltero, Richard	3-20-2003
WO 03/022210	A2	Soltero, Richard	3-20-2003
WO 03/022210	A3	Soltero, Richard	3-20-2003
WO 03/022996	A2	Soltero, Richard	3-20-2003
DE 19632440	A1	Gehrer, Eugen	2-19-1998

TRH 676091v1	/Samuel Liu/	Date Considered	10/25/2010
--------------	--------------	-----------------	------------

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute	form 1449A/PTO		C	omplete if Known
INFORMATION DISCLOSURE		Application Number	10/562,478	
INFORM	ATION DISCL	OSURE	Filing Date	11-15-2006
STATE	STATEMENT BY APPLICANT		First Named Inventor	Gordana Kosutic
			Group Art Unit	1656
(use as ma	any sheets as nec	essary)	Examiner Name	Liu, Samuel
Sheet	6		Attorney Docket Number	014811-487.114

		OTHER NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T
		Banting et al., "Pancreatic Extracts in the Treatment of Diabetes Mellitus," Can. Med. Assoc. 1, 12: 141-146 (1922).	
		Coudert et al., "A Novel, Unequivocal Synthesis of Polyethylene Glycols," Synthetic Communications, 16(1): 19-26 (1986).	
		Francis, G.E., et al., Polyethylene Glycol Modification: Relevance of Improved Methodology to Tumour Targeting, <i>Journal of Drug Targeting</i> , vol. 3, pp. 321-340 (1996).	
		Guzman, Angel, et al., Effects of Fatty Ethers and Stearic Acid of the Gastrointestinal Absorption of Insulin, <i>PRHSJ</i> , vol. 9, No. 2, pp. 155-159 (Aug. 1990).	
		H. Allcock & F. Lampe, "Contemporary Polymer Chemistry," 394403 (2nd. ed., 1991).	
		J. Milton Harris, "Laboratory Synthesis of Polyethylene Glycol Derivatives," J. Macromol. Science Rev. Macromol. Chem. Phys., C25(3): 325-373 (1985).	
		Krishnan, B. Radha, et al., Stability and Physical Characteristics of Orally Active Amphiphilic Human Insulin Analog, Methoxy (Polyethylene Glycol) Hexanoyl Human Recombinant Insulin (HIM2), <i>Proceed. Intl. Symp. Control. Rel. Bioact. Mater.</i> , vol. 27 pp. 1038-1039 (2000).	
		Lindsay, D.G., et al., The Acetylaton of Insulin, <i>Biochem J.</i> vol. 121, pp. 737-745 (1971).	
		Mesiha, M.S., et al., Hypoglycaemic effect of oral insulin preparations containing Brij 35, 52, 58 or 92 and stearic acid, <i>J. Pharm. Pharmacol.</i> , vol. 33, pp. 733-734 (1981).	
		Moghaddam, Amir, Use of polyethylene glycol polymers for bioconjugations and drug development, American Biotechnology Laboratory, pp. 42, 44 (Jul. 2001).	
		Neubauer, H. Paul, et al., Influence of Polyethylene Glycol Insulin on Lipid Tissues of Experimental Animals, <i>Diabetes</i> , vol. 32, pp. 953-958 (Oct. 1983).	
		Shen, Wei-Chiang, et al., (C) Means to Enhance Penetration; (3) Enhancement of polypeptide and protein absorption by macromolecular carriers via endocytosis and transcytosis, <i>Advanced Drug Delivery Reviews</i> , vol. 8, pp. 93-113 (1992).	
		Sirokman, Geza, et al., Refolding and proton pumping activity of a polyethylene glycolbacteriorhodopsin water-soluble conjugate, <i>Protein Science</i> , vol. 2, pp. 1161-1170 (1993).	
		Torchilin, Vladimir P., Immunoliposomes and PEGylated Immunoliposomes: Possible Use for Targeted Delivery of Imaging Agents, <i>Immunomethods</i> , vol. 4, pp. 244-258 (1994).	
		Wei, Jiang, et al., A Poly(Ethylene Glycol) Water-soluble Conjugate of Porin:	

- 1				
	TRU 676091vi	/Samuel Liu/	Date Considered	10/25/2010

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute	Substitute form 1449A/PTO		C	omplete if Known	
ILIPARE ATIAL BIOAL ACTION		Application Number	10/562,478		
INFORMATION DISCLOSURE	Filing Date	11-15-2006			
STATE	STATEMENT BY APPLICANT	First Named Inventor	Gordana Kosutic		
		Group Art Unit	1656		
(use as many sheets as necessary)		Examiner Name	Liu, Samuel		
Sheet	7		Attorney Docket Number	014811-487.114	

Refolding to the Native State, <i>Biochemistry</i> , vol. 34, pp. 6408-6415 (1995).	
Xia, Jiding, et al., Effects of polyoxyethylene chain length distribution on the interfacial properties of polyethylene glycol n-dodecyl ether, <i>Yinghong Huaxue</i> , vol. 2, No. 4, pp. 59-65 (Abstract Only) (1985).	
Y. Chen & G. Baker, "Synthesis and Properties of AMA Amphiphiles," J. Org. Chem., 64: 6870-6873 (1999).	
Zalipsky, Samuel, et al., Peptide Attachment to Extremities of Liposomal Surface Grafted PEG Chains: Preparation of the Long-Circulating Form of Laminin Pentapeptide, YIGSR, <i>Bioconjugate Chem.</i> , vol. 6, pp. 705-708 (1995).	
Baudy et al., "Stabilization and intestinal absorption of human calcitonin," <i>Journal of Controlled Release</i> 39: 145-151 (1996).	
Hinds et al., Synthesis and Characterization of Polyethylene glycol)-Insulin, Bioconjugate Chem., vol. 11, 2000, pp. 195-201.	
Abuchowski, A. and F. F. Davis "Soluble Polymer-Enzyme Adducts" pp. 367-383, Enzymes as Drugs, Ed. J. S. Holcenberg, John Wiley (1981).	
Agarwal et al. "Polymethyacrylate-based Microparticulates of Insulin for Oral Delivery: Preparation and In Vitro Dissolution Stability in the Presence of Enzyme Inhibitors" <i>International Journal of Pharmaceutics</i> 225:31-39 (2001).	
Akiyama et al. "The Synthesis of New Derivatives of 1-13-DArabinofuranosylcytosine" <i>Chem. Pharm. Bull.</i> 26(3):981-984 (1978).	
Allaudeen et al. "Orally Active Insulin: A Single Insulin Conjugate Selected for Future Studies" 60th Annual Meeting of the American Diabetes Assoc., Atlanta, GA, Jun. 2000 (Abstract).	
Anderson et al. "HIM2, a Novel Modified Insulin, has Improved Systemic Pharmacokinetics in Normal Dogs, Compared to Unmodified Insulin" American Diabetes Association 62nd Annual Meeting, Jun. 2002 (Abstract).	
Ansell et al. "Application of Oligo-(14-amino-3,6,9,12- tetraoxatetradecanoic acid) Lipid Conjugates as Steric Barrier Molecules in Liposomal Formulations" <i>Bioconjugate Chem.</i> 10:653-666 (1999).	
Aoshima et al. "N ⁴ -Behenoy1-1-13-D-Arabinofuranosylcytosine as a Potential New Antitumor Agent" <i>Cancer Research</i> 37:2481-2486 (1977).	
Banting et al. "Pancreatic Extracts in the Treatment of Diabetes Mellitus: Preliminary Report" Can. Med. Assoc. J. 145(10):1281-1286 (1991).	
Baudys et al. "Stabilization and Intestinal Absorption of Human Calcitonin" <i>J. Control. Rel.</i> 39:145-151 (1996).	
Baudys et al. "Synthesis and Characterization of Different Glycosylated Derivatives of Insulin"Proceed <i>Intern Symp. Cont. Rd. Bioactive Mater.</i> 19:210-211 (1992).	
Baker, D. C. et al. "Prodrugs of 9-13-D-Arabinofuranosyladenine. 1. Synthesis and Evaluation of Some 5'-(0 Acyl) Derivatives" <i>J. Med. Chem.</i> 21(12):1218-1221	

TRIE676091v1	/Samuel Liu/	Date Considered	10/25/2010
1			

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute	Substitute form 1449A/PTO		C	omplete if Known	
HIPARIA TIALI BIOAL AOLINE		Application Number	10/562,478		
INFORMATION DISCLOSURE	Filing Date	11-15-2006			
STATE	STATEMENT BY APPLICANT	First Named Inventor	Gordana Kosutic		
		Group Art Unit	1656		
(use as many sheets as necessary)		Examiner Name	Liu, Samuel		
Sheet	8		Attorney Docket Number	014811-487.114	

	(1978).
	Boccu et al. "Pharmacokinetic Properties of Polyethylene Glycol Derivatized Superoxide Di smutase"Pharm. Res. Comm. 14:113 -120 (1982).
	Bone et al. "Successful Treatment of an Insulin Dependent Rat Model of Human Type 1 Diabetes with Orally Active Insulin" Program and Abstracts, 4th International Workshop on Lessons from Animal Diabetes, Omiya, Japan, Nov. 1994 (Abstact).
	Brange and Volund "Insulin Analogs with Improved Pharmacokinet c Profiles" Adv anced Drug Delivery Reviews 35:307335 (1999).
	Brange et al. "Chemical Stability of Insulin. 1. Hydrolytic Degradation During Storage of Pharmaceutical Preparations" <i>Pharm. Res.</i> 9(6):715-726 (1992).
	Brange et al. "Chemical Stability of Insulin. 2. Formation of Higher Molecular Weight Transformation Product During Storage of Pharmaceutical Preparations" <i>Pharm. Res.</i> 9(6):727-734 (1992).
	Brange, J. "Galenics of Insulin: The Physico-Chemical and Pharmaceutical Aspects of Insulin and Insulin Preparations" Novo Research Institute, Denmark, pp. 18-100 (1987).
	Chien, Y. W., Novel Drug Delivery Systems, pp. 678-679, Marcell Deffer, Inc., New York, N.Y. (1992).
	Cleland et al. "Emerging Protein Delivery Methods" Current Opinion in Biotechnology 12:212-219 (2001).
	Clement et al. "Effects of Multiple Doses of Orally Administered Hexyl Insulin M2 (HIM2) on Postprandial Blood Glucose (PPG) Concentrations in Type 1 Diabetic (Ti) Patients" American Diabetes Association 62nd Annual Meeting, Jun. 2002 (Poster).
	Clement et al. "Oral Insulin Product Hexyl-Insulin Monoconjugate 2 (HIM2) in Type 1 Diabetes Mellitus: The Glucose Stabilization Effects of HIM2"Diabetes Technology & Therapeutics 4(4):459-466 (2002).
	Clement, Stephen "A Dose-Escalation Study of the Effects of Two Sequential Doses of Oral Modified Insulin on Blood Glucose Concentrations in Patients with Type 1 Diabetes Mellitus" American Diabetes Association Annual Meeting (Jun. 25, 2001) (Abstract).
	Clement, Stephen "A Dose-Escalation Study of the Effects of Two Sequential Doses of Oral Modified Insulin on Blood Glucose Concentrations in Patients with Type 1 Diabetes Mellitus" American Diabetes Association Annual Meeting (Jun. 25, 2001) (Poster).
	Conradi et al. "The Influence of Peptide Structure on Transport Across Caco-2 Cells" <i>Pharm. Res.</i> 8(12):1453-1459 (1991).
	Coombes et al. "Biodegradable Polymeric Microparticles for Drug Delivery and Vaccine Formulation: the Surface Attachment of Hydrophilic Species Using the Concept of Poly(Ethylene Glycol) Anchoring Segments" Biomaterials 18:1153 -
2002112000000015.2	Y

·		/XXXX		ŭ.
TR1:(67609) v i	/Samuel Liu/	Date Considered	10/25/2010	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute	Substitute form 1449A/PTO		C	omplete if Known	
	16100000000000000000000000000000000000		Application Number	10/562,478	
INFORMATION DISCLOSURE	Filing Date	11-15-2006			
STATE	STATEMENT BY APPLICANT	First Named Inventor	Gordana Kosutic		
		Group Art Unit	1656		
(use as many sheets as necessary)		Examiner Name	Liu, Samuel		
Sheet	9		Attorney Docket Number	014811-487.114	

1161 (1997).
Damge et al. "Poly(alkyl cyanoacrylate) Nanospheres for Oral Administration of Insulin" <i>Journal of Pharmaceutical Sciences</i> 86(12):1403-1409 (Dec. 1997).
Dandona et al. "Effect of an Oral Modified Insulin on Blood Glucose Levels in Fasting and Fed Type 1 Diabetic Patients Receiving a 'Basal' Regimen of Injected Insulin' American Diabetes Association Annual Meeting (Jun. 25, 2001) (Abstract).
Delgado et al. "The Uses and Properties of PEG-Linked Proteins" Critical Reviews in Therapeutic Drug Carrier Systems 9(3,4):249304 (1992).
Ekwuribe, Nnochiri "Conjugation-Stabilized Polypeptide Compositions, Therapeutic Delivery and Diagnostic Formulations Comprising Same, and Method of Making and Using the Same" <i>Biotechnology Advances</i> 14(4):575-576 (1996) (Abstract).
Engel et al. "Insulin: Intestinal Absorption as Water-in-Oil-in-Water Emulsions" <i>Nature</i> 219:856-857 (1968).
Fasano, Alessio "Innovative strategies for the oral delivery of drugs and peptides" <i>TIBTECH</i> 16:152-157 (1998).
Forst et al. "New Aspects on Biological Activity of C-peptide in IDDM Patients" Exp. Clin. Endocrinol. Diabetes 106:270-276 (1998).
Gish et al. "Nucleic Acids. 11. Synthesis of 5'-Esters of 1-13-D-Arabino furano sylcyto sine Possessing Antileukemic and Immuno suppressive Activity" <i>J. Med. Chem.</i> 14(12): 1159-1162 (1971).
Gombotz & Pettit "Biodegradable Polymers for Protein and Peptide Drug Delivery" Bioconjugate Chem. 6:332-351 (1995).
Hashimoto et al. "Synthesis of Palmitoyl Derivatives of Insulin and Their Biological Activities" <i>Pharmaceutical Research</i> 6(2):171-176 (1989).
Hong et al. "Nucleoside Conjugates. 7. Synthesis and Antitumor Activity of 1-13-D-Arabinofuranosylcytosine Conjugates of Ether Lipids" <i>J. Med Chem.</i> 29:2038-2044 (1986).
Hostetler et al. "Synthesis and Antiretroviral Activity of Phospholipid Analogs of Azidothymidine and Other Antiviral Nucleosides" <i>The Journal of Biological Chemistry</i> 265(11):61126117 (1990).
Igarashi et al. "Biologically Active Peptides Conjugated with Lecithin for DDS" Proceed. Intern. Symp. Cont. Rd. Bioactiv. Mater 17:367-368 (1990).
Kemmler et al. "On the Nature and Subcellular Localization of the Proinsulin Converting Enzymes" Federation Proceedings 30(Abstract 924):1210Abs (1971).
Kemmler et al. "Studies on the Conversion of Proinsulin to Insulin: I. Converison in Vitro with Tiypsin and Carboxypeptidase B" <i>The Journal of Biological Chemistry</i> 246(22):6786-6791 (1971).
King et al. "Preparation of Protein Conjugates with Alkoxypolyethylene Glycols" Int. J. Peptide Protein Res. 16:147155 (1980).

TR11/676091v1	/Samuel Liu/	Date Considered	10/25/2010	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute	Substitute form 1449A/PTO		(omplete if Known	
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number	10/562,478		
INFORM		Filing Date	11-15-2006		
STATE		First Named Inventor	Gordana Kosutic		
		Group Art Unit	1656		
(use as m	(use as many sheets as necessary)		Examiner Name	Liu, Samuel	
Sheet	10		Attorney Docket Number	014811-487.114	

Kipnes et al. "Control of Postprandial Plasma Glucose by an Oral Insulin Product	
(HIM2) in Patients with Type 2 Diabetes" <i>Emerging Treatments and Technologies</i> 26:2 (2003).	
Kipnes et al. "The Effects of an Oral Modified Insulin on Postprandial Blood Glucose Levels in Patients with Type 2 Diabetes Mellitus" American Diabetes Association Annual Meeting (Jun. 2001) (Poster).	
Kipnes et al. "The Effects of an Oral Modified Insuling on Postprandial Blood Glucose Levels in Patients with Type 2 Diabetes" American Diabetes Association Annual Meeting (Jun. 24, 2001) (Abstract).	
Kube, D.M. "Multitalented Proteins Play a Key Role in Therapeutics" <i>Genomics and Proteomics</i> (Sep. 2002).	
Maislos et al. "The Source of the Circulating Aggregate of Insulin in Type I Diabetic Patients is Therapeutic Insulin" <i>J. Clin. Invest.</i> 77:717-723 (1986).	
Marschutz et al. "Oral Peptide Drug Delivery: Polymer-Inhibitor Conjugates Protecting Insulin from Enzymatic Degradation In Vitro" <i>Biomaterials</i> 21:1499-1507 (2000).	
Musabayane et al. "Orally Administered, Insulin-Loaded Amidated Pectin Hydrogel Beads Sustain Plasma Concentrations of Insulin in Streptozotocin-Diabetic Rats" Journal of Endocrinology 164:1-6 (2000).	
Nucci et al. "The Therapeutic Value of Poly(ethylene Glycol) Modified Proteins" Ad. Drug. Del. Rev. 6:133-151 (1991).	
Oka et al. "Enhanced Intestinal Absorption of a Hydrophobic Polymer-Conjugated Protein Drug, Smancs, in an Oily Formulation" <i>Pharm. Res.</i> 7(8):852-855 (1990).	
Pang, David C. "Bridging Gaps in Drug Discovery and Development" Pharmaceutical Technology 22:82-94 (Nov. 1998).	
Patel et al. "Oral Administration of Insulin by Encapsulation Within Liposomes" <i>FEBS Lett.</i> 62(1):60-63 (1976).	
Puskas et al. "Investigation of Chymotrypsin Digestion Profile of Orally Active Insulin Conjugate HIM2"AAPSPharm Sci. 3(3) 2001 (Abstract).	
Radhakrishnan et al. "Chemical Modification of Insulin with Amphiphilic Polymers Improves Intestinal Delivery," <i>Proceed. Intl. Symp. Control. Rd. Bioact. Mater</i> 25:124-125(1998) (Abstract).	******

TRI1/676091v1	/Samuel Liu/	Date Considered	10/25/2010
	/Samuel Liu/		10/25/2010

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.